Is HYPOGLYCAEMIA a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed HYPOGLYCAEMIA.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 76 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported HYPOGLYCAEMIA to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and HYPOGLYCAEMIA. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause HYPOGLYCAEMIA, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes HYPOGLYCAEMIA. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if HYPOGLYCAEMIA ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing HYPOGLYCAEMIA: 76
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where HYPOGLYCAEMIA is a reported side effect: 2.2830%

FDA reports of any drug causing HYPOGLYCAEMIA : 19480
Average percentage for all medicated patients where HYPOGLYCAEMIA is reported as a complication: 0.1221%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
DESMOID TUMOUR ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
SARCOMA ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with HYPOGLYCAEMIA:

LANTUS (3534 patients)
ASPIRIN (2286 patients)
SEROQUEL (2107 patients)
HUMALOG (1637 patients)
METFORMIN HCL (1621 patients)
INSULIN (1272 patients)
GLYBURIDE (1233 patients)
AMARYL (1217 patients)
LASIX (1111 patients)
FUROSEMIDE (899 patients)
JANUVIA (856 patients)
FOSAMAX (832 patients)
BYETTA (802 patients)
SIMVASTATIN (794 patients)
LISINOPRIL (792 patients)
LIPITOR (779 patients)
GLUCOPHAGE (708 patients)
ZYPREXA (661 patients)
ACTOS (639 patients)
OMEPRAZOLE (625 patients)
GLIPIZIDE (620 patients)
AVANDIA (568 patients)
METFORMIN (549 patients)
HEPARIN SODIUM INJECTION (545 patients)
HYDROCHLOROTHIAZIDE (511 patients)
NOVORAPID (495 patients)
SYNTHROID (486 patients)
NORVASC (485 patients)
PLAVIX (483 patients)
ATENOLOL (480 patients)
NOVOLOG (479 patients)
VIOXX (472 patients)
ALLOPURINOL (459 patients)
DIGOXIN (455 patients)
ACETAMINOPHEN (446 patients)
DIOVAN (440 patients)
LEVEMIR (426 patients)
LEVOTHYROXINE SODIUM (414 patients)
HUMULIN R (409 patients)
COUMADIN (409 patients)
ZOCOR (408 patients)
HUMULIN N (408 patients)
RISPERDAL (402 patients)
GLIMEPIRIDE (399 patients)
PREDNISONE (387 patients)
NEURONTIN (377 patients)
AMLODIPINE (348 patients)
TEQUIN (343 patients)
ZOLOFT (331 patients)
RAMIPRIL (328 patients)
NEXIUM (325 patients)
ENALAPRIL MALEATE (325 patients)
POTASSIUM CHLORIDE (311 patients)
HUMALOG MIX 75/25 (308 patients)
XANAX (304 patients)
LYRICA (302 patients)
WARFARIN SODIUM (290 patients)
PAXIL (290 patients)
COZAAR (290 patients)
PREDNISOLONE (287 patients)
FOLIC ACID (283 patients)
ALDACTONE (281 patients)
LANSOPRAZOLE (274 patients)
INSULIN GLARGINE (274 patients)
COREG (274 patients)
APIDRA (270 patients)
SOLOSTAR (269 patients)
METOPROLOL TARTRATE (269 patients)
PROTONIX (264 patients)
DIANEAL (254 patients)
AMBIEN (253 patients)
PREVACID (251 patients)
LEVAQUIN (250 patients)
DEPAKOTE (249 patients)
NOVOLIN R (245 patients)
CARVEDILOL (245 patients)
CRESTOR (244 patients)
ALPRAZOLAM (244 patients)
SPIRONOLACTONE (240 patients)
METFORMIN HYDROCHLORIDE (240 patients)
ALBUTEROL (240 patients)
NITROGLYCERIN (239 patients)
GABAPENTIN (238 patients)
ZOMETA (236 patients)
LEXAPRO (234 patients)
SANDOSTATIN LAR (233 patients)
METOPROLOL (232 patients)
NEXAVAR (229 patients)
GLICLAZIDE (221 patients)
METHOTREXATE (218 patients)
TOPROL-XL (217 patients)
ALTACE (217 patients)
CYMBALTA (214 patients)
CLONAZEPAM (213 patients)
LORAZEPAM (211 patients)
REMICADE (211 patients)
PRILOSEC (210 patients)
MICARDIS (207 patients)
TRAMADOL HCL (206 patients)
CITALOPRAM HYDROBROMIDE (203 patients)
GATIFLOXACIN (201 patients)
AMOXICILLIN (201 patients)
CIPROFLOXACIN (199 patients)
EFFEXOR (196 patients)
IBUPROFEN (195 patients)
ZETIA (192 patients)
CELEXA (191 patients)
BASEN (190 patients)
GLUCOVANCE (188 patients)
BISOPROLOL FUMARATE (187 patients)
GLIBENCLAMIDE (186 patients)
PROZAC (183 patients)
LEVOFLOXACIN (182 patients)
AVELOX (180 patients)
SINGULAIR (179 patients)
ACETYLSALICYLIC ACID SRT (176 patients)
FERROUS SULFATE TAB (176 patients)
WELLBUTRIN (169 patients)
EXTRANEAL (168 patients)
ABILIFY (168 patients)
DEXAMETHASONE (166 patients)
TRAZODONE HCL (165 patients)
PROPRANOLOL (163 patients)
HUMULIN 70/30 (159 patients)
VICODIN (157 patients)
NOVOLIN N (152 patients)
SYMLIN (151 patients)
CLONIDINE (151 patients)
AMITRIPTYLINE HCL (150 patients)
ATIVAN (150 patients)
METOCLOPRAMIDE (150 patients)
AMLODIPINE BESYLATE (147 patients)
TEMAZEPAM (146 patients)
GEODON (146 patients)
PREDNISONE TAB (146 patients)
CLARITHROMYCIN (146 patients)
PERCOCET (145 patients)
NOVOLOG MIX 70/30 (145 patients)
FAMOTIDINE (144 patients)
RANITIDINE (144 patients)
RISPERIDONE (143 patients)
CELEBREX (143 patients)
CAPTOPRIL (142 patients)
DIAZEPAM (142 patients)
ADVAIR DISKUS 100/50 (141 patients)
DIAMICRON (141 patients)
REGLAN (141 patients)
ATORVASTATIN CALCIUM (141 patients)
ZANTAC (140 patients)
NPH INSULIN (138 patients)
PEPCID (137 patients)
ACCUTANE (136 patients)
ADALAT (135 patients)
GLUCOBAY (135 patients)
PREDONINE (134 patients)
NOVORAPID CHU FLEXPEN (133 patients)
ATORVASTATIN (133 patients)
ZOFRAN (133 patients)
VERAPAMIL (131 patients)
NIFEDIPINE (131 patients)
MAGNESIUM OXIDE (131 patients)
KLONOPIN (130 patients)
LORTAB (128 patients)
GLEEVEC (128 patients)
TRICOR (126 patients)
FLUCONAZOLE (126 patients)
[THERAPY UNSPECIFIED] (126 patients)
OXYCODONE HCL (125 patients)
CLOPIDOGREL (125 patients)
OPTICLIK (INSULIN INJECTION PEN) (124 patients)
AREDIA (124 patients)
IRBESARTAN (123 patients)
METOPROLOL SUCCINATE (123 patients)
COLACE (123 patients)
VITAMIN D (123 patients)
LOPRESSOR (121 patients)
MORPHINE (121 patients)
ZYRTEC (121 patients)
DECADRON (120 patients)
ENALAPRIL (119 patients)
REGULAR INSULIN (119 patients)
GLUCOTROL (119 patients)
REPAGLINIDE (119 patients)
TORSEMIDE (119 patients)
OPTIPEN (INSULIN PUMP) (118 patients)
PANTOPRAZOLE SODIUM (118 patients)
TOPAMAX (118 patients)
FORTEO (118 patients)
LOSARTAN POTASSIUM (117 patients)
NAPROXEN (116 patients)
VALSARTAN (116 patients)
CALCIUM CARBONATE (116 patients)
PRAVASTATIN (115 patients)
LAMICTAL (115 patients)
HEPARIN (115 patients)
NOVONORM (115 patients)
HYDROCORTISONE (114 patients)
VELCADE (113 patients)
VYTORIN (113 patients)
LOVENOX (112 patients)
AMIODARONE HCL (112 patients)
HUMIRA (112 patients)
FLUOXETINE (111 patients)
ALLEGRA (111 patients)
NOVORAPID FLEXPEN (110 patients)
ACTRAPID (110 patients)
MUCOSTA (110 patients)
VICTOZA (109 patients)
AVAPRO (108 patients)
PANTOPRAZOLE (107 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about HYPOGLYCAEMIA and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.